Showing 101-110 of 3035 results for "".
The Case for JAK Inhibitors to Treat AD
https://practicaldermatology.com/topics/atopic-dermatitis/case-jak-inhibitors-treat-ad/27109/E. James Song, MD, FAAD, Director of Clinical Research and Co-Chief Medical Officer for Frontier Dermatology, discusses his presentation “JAK Inhibitors in Atopic Dermatitis” from the 2024 American Academy of Dermatology (AAD) Innovation Academy.Noah Worcester 2024: Dr. Bridges on Practice Management
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-bridges-practice-management/24580/Alina Bridges, DO, FAAD, summarizes her lecture on practice management and coding at the 2024 Noah Worcester Dermatological Society meeting.What Every Dermatologist Must Know About the History of Black Hair
https://practicaldermatology.com/topics/hair-nails/what-every-dermatologist-must-know-about-the-history-of-black-hair/23996/Knowledge of the historical, cultural, and social significance of hairstyles of Black patients may reduce implicit bias amongst dermatologists. In this article, Brooke Jackson, MD, FAAD, and Aliya Rodriguez, BS, explore the unique history and cultral impact of black hair.Journal Club: Biologics for Young Children
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-biologics-for-young-children/32400/Practical Dermatology Editorial Board member Lawrence Eichenfield, MD, FAAD, Dawn Eichenfield, MD, PhD, discuss the article "Biologic therapies in infants and children younger than 6 years of age with atopic dermatitis: suitability and practical considerations," from Expert Opinion on Drug Safety. RJournal Club: Dupilumab and Risk of Malignancy
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national databaseAsk an Expert: Sheila Fallon Friedlander, MD on the Molluscum Pipeline
https://practicaldermatology.com/topics/general-topics/ask-an-expert-sheila-fallon-friedlander-md-on-the-molluscum-pipeline/19006/Sheila Fallon Friedlander, MD talks to host Adam Friedman, MD about the pipeline of treatments for molluscum in pediatric patients. From NewDermMD.DERM2020 Content Recap: Adam Friedman, MD
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-content-recap-adam-friedman/19839/DERM2020 Faculty Adam Friedman, MD shares his thoughts on DERM2020 and some of his content.DERM2020 Content Recap: Julie Harper, MD
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-content-recap-julie-harper-md/19844/DERM20920 Faculty Julie Harper, MD discusses what’s new in rosacea from her presentation during DERM2020.DERM2020 Content Recap: Linda Stein Gold, MD
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-content-recap-linda-stein-gold-md/19845/DERM2020 Faculty Linda Stein Gold, MD discusses what’s new in acne from her presentation during DERM2020.Scientifically Speaking: Effective By Design with Josh Makower, MD
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-effective-by-design-with-josh-makower-md/20106/Josh Makower, MD has been at the forefront of several medical innovations. Listen in as he describes his approach and discusses his latest product with host Joel L. Cohen, MD. The Avéli device from Revelle Aesthetics is FDA-cleared to reduce cellulite in the buttocks and thighs temporarily.